DB:DUL

Stock Analysis Report

Executive Summary

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics.


Snowflake Analysis

Excellent balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Alnylam Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DUL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.7%

DUL

-2.3%

DE Biotechs

-0.2%

DE Market


1 Year Return

73.8%

DUL

8.4%

DE Biotechs

13.7%

DE Market

Return vs Industry: DUL exceeded the German Biotechs industry which returned 9% over the past year.

Return vs Market: DUL exceeded the German Market which returned 14.4% over the past year.


Shareholder returns

DULIndustryMarket
7 Day-2.7%-2.3%-0.2%
30 Day13.8%-3.2%0.3%
90 Day18.8%6.3%3.7%
1 Year73.8%73.8%8.6%8.4%17.2%13.7%
3 Year174.3%174.3%44.5%42.9%15.4%5.3%
5 Year27.3%27.3%13.0%10.6%21.3%4.7%

Price Volatility Vs. Market

How volatile is Alnylam Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Alnylam Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

49.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: DUL (€118.36) is trading below our estimate of fair value (€236.47)

Significantly Below Fair Value: DUL is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: DUL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: DUL is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DUL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DUL is overvalued based on its PB Ratio (10.1x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Alnylam Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?

58.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DUL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DUL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DUL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DUL's revenue (39.6% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: DUL's revenue (39.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: DUL is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Alnylam Pharmaceuticals performed over the past 5 years?

-27.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DUL is currently unprofitable.

Growing Profit Margin: DUL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DUL is unprofitable, and losses have increased over the past 5 years at a rate of -27.9% per year.

Accelerating Growth: Unable to compare DUL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DUL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: DUL has a negative Return on Equity (-61.59%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Alnylam Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: DUL's short term assets ($1.7B) exceed its short term liabilities ($352.6M).

Long Term Liabilities: DUL's short term assets ($1.7B) exceed its long term liabilities ($603.8M).


Debt to Equity History and Analysis

Debt Level: DUL is debt free.

Reducing Debt: DUL had no debt 5 years ago.


Balance Sheet

Inventory Level: DUL has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if DUL's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DUL has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if DUL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Alnylam Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DUL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate DUL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DUL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DUL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DUL's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

John Maraganore (56yo)

17.2yrs

Tenure

US$5,089,269

Compensation

Dr. John M. Maraganore, M.D., Ph.D. was an Advisor at Flex Pharma, Inc. Dr. Maraganore has been the Chief Executive Officer and Executive Director at Alnylam Pharmaceuticals, Inc. since December 2002. He h ...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD5.09M) is about average for companies of similar size in the German market ($USD4.31M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
John Maraganore
CEO & Executive Director17.2yrsUS$5.09m0.17% $23.1m
Barry Greene
President12.2yrsUS$2.99m0.058% $7.8m
Yvonne Greenstreet
Executive VP & COO3.4yrsUS$2.68m0.0021% $277.2k
Akshay Vaishnaw
President of Research & Development11.2yrsUS$2.62m0.010% $1.4m
Jeffrey Poulton
Executive VP & CFO0.5yrsno datano data
Al Boyle
Senior Vice President of Technical Operations0yrsno datano data
Kevin Fitzgerald
Senior VP & Chief Scientific Officer0.8yrsno datano data
Christine Lindenboom
Vice President of Investor Relations & Communications0yrsno datano data
Laurie Keating
Executive VP5.4yrsUS$5.31m0.011% $1.5m
Nereyda Garcia
Global Head of Ethics & Compliance4.1yrsno datano data

4.8yrs

Average Tenure

56yo

Average Age

Experienced Management: DUL's management team is considered experienced (4.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
John Maraganore
CEO & Executive Director17.2yrsUS$5.09m0.17% $23.1m
Muthiah Manoharan
Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board4.3yrsno datano data
Michael Bonney
Independent Chairman4.2yrsUS$704.92k0.0036% $477.7k
Paul Schimmel
Member of the Scientific Advisory Board & Director17.7yrsUS$676.80k0.27% $36.7m
David E. Pyott
Independent Director4.2yrsUS$672.42k0.025% $3.3m
Phillip Sharp
Co-Founder0yrsUS$697.42k0.24% $31.9m
Thomas Tuschl
Member of Scientific Advisory Board0yrsno datano data
Marsha Fanucci
Independent Director9.2yrsUS$688.67kno data
Amy Schulman
Independent Director5.6yrsUS$684.92kno data
Phillip Zamore
Member of Scientific Advisory Board0yrsno datano data

5.6yrs

Average Tenure

65.5yo

Average Age

Experienced Board: DUL's board of directors are considered experienced (5.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.6%.


Top Shareholders

Company Information

Alnylam Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Alnylam Pharmaceuticals, Inc.
  • Ticker: DUL
  • Exchange: DB
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$14.523b
  • Listing Market Cap: US$13.457b
  • Shares outstanding: 112.58m
  • Website: https://www.alnylam.com

Number of Employees


Location

  • Alnylam Pharmaceuticals, Inc.
  • 675 West Kendall Street
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALNYNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2004
DULDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2004
DULXTRA (XETRA Trading Platform)YesCommon StockDEEURMay 2004
0HD2LSE (London Stock Exchange)YesCommon StockGBUSDMay 2004
DULBRSE (Berne Stock Exchange)YesCommon StockCHCHFMay 2004
ALNY *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNMay 2004

Biography

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company’s pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The company’s development programs include Vutrisiran, an investigational RNAi therapeutic targeting transthyretin that is in Phase III trials for the treatment of transthyretin-mediated amyloidosis; GIVLAARI (Givosiran) that is in Phase III trials to treat acute hepatic porphyrias; and Lumasiran, an investigational RNAi therapeutic, which is in Phase III clinical trials for glycolate oxidase to treat primary hyperoxaluria type 1. It is also developing Inclisiran, an investigational RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9 that is in Phase III clinical trials for the treatment of hypercholesterolemia; and Fitusiran, an investigational RNAi therapeutic that is in Phase III clinical trials for treating hemophilia A and B with or without inhibitors. In addition, the company engages in the development of Cemdisiran for complement-mediated diseases; ALN-AAT02 to treat alpha-1 anti-trypsin deficiency-associated liver disease; ALN-HBV02 for treating chronic hepatitis B virus infection; and other earlier-stage programs. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Vir Biotechnology, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 20:36
End of Day Share Price2020/02/20 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.